CoChat

Functional Investigations of p53 Acetylation Enabled by Heterobifunctional Molecules

Open access
Chen, Li-Yun, Singha Roy, Soumya Jyoti, Jadhav, Appaso M., Wang, Wesley W., Chen, Pei-Hsin, Bishop, Timothy, Erb, Michael A., Parker, Christopher G. · 2024 · ACS Chemical Biology

The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.

Abstract

Post-translational modifications (PTMs) dynamically regulate the critical stress response and tumor suppressive functions of p53. Among these, acetylation events mediated by multiple acetyltransferases lead to differential target gene activation and subsequent cell fate. However, our understanding of these events is incomplete due to, in part, the inability to selectively and dynamically control p53 acetylation. We recently developed a heterobifunctional small molecule system, AceTAG, to direct the acetyltransferase p300/CBP for targeted protein acetylation in cells. Here, we expand AceTAG to leverage the acetyltransferase PCAF/GCN5 and apply these tools to investigate the functional consequences of targeted p53 acetylation in human cancer cells. We demonstrate that the recruitment of p300/CBP or PCAF/GCN5 to p53 results in distinct acetylation events and differentiated transcriptional activities. Further, we show that chemically induced acetylation of multiple hotspot p53 mutants results in increased stabilization and enhancement of transcriptional activity. Collectively, these studies demonstrate the utility of AceTAG for functional investigations of protein acetylation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acschembio.4c00438

Cites

118 of 118 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PCAF/GCN5 recruiting AceTAG molecules mediate ternary complex formation and induce acetylation of FKBP12F36 V tagged p53 in cells. (a) Schematic overview of targeted acetylation tagging (AceTAG) strategy. (b) Structure of AceTAGPCAF/GCN5 molecules composed of PCAF/GCN5 bromodomain ligand, an L-Moses derivative, and FKBP12F36 V binding ligand with different linker compositions. (c) AceTAGPCAF/GCN5 molecules induce ternary complex formation between PCAF bromodomain and FKBP12F36 V recombinant protein in vitro as determined by AlphaScreen. Data are plotted as mean ± s.d. of n = 3 replicates. (d) AceTAGPCAF/GCN5 molecules induce p53-FKBP12F36 V acetylation in cells. Doxycycline-inducible p53-FKBP12F36 V-HA cells were pretreated with 1 μg/mL doxycycline or vehicle for 16 h and treated with increasing concentration of AceTAGPCAF/GCN5-4 for 2 h. p53-FKBP12F36 V-HA was immunoprecipitated and acetylation monitored via immunoblotting. Results are representative of two independent biological replicates. Statistical significance was calculated with unpaired two-tailed Student’s t tests comparing DMSO- to AceTAGp300/CBP-1-treated samples.*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Data are plotted as mean ± s.d. of n = 2 independent biological replicates. Full image of immunoblots are shown in Figure S6.
Figure 1 PCAF/GCN5 recruiting AceTAG molecules mediate ternary complex formation and induce acetylation of FKBP12F36 V tagged p53 in cells. (a) Schematic overview of targeted acetylation tagging (AceTAG) strategy. (b) Structure of AceTAGPCAF/GCN5 molecules composed of PCAF/GCN5 bromodomain ligand, an L-Moses derivative, and FKBP12F36 V binding ligand with different linker compositions. (c) AceTAGPCAF/GCN5 molecules induce ternary complex formation between PCAF bromodomain and FKBP12F36 V recombinant protein in vitro as determined by AlphaScreen. Data are plotted as mean ± s.d. of n = 3 replicates. (d) AceTAGPCAF/GCN5 molecules induce p53-FKBP12F36 V acetylation in cells. Doxycycline-inducible p53-FKBP12F36 V-HA cells were pretreated with 1 μg/mL doxycycline or vehicle for 16 h and treated with increasing concentration of AceTAGPCAF/GCN5-4 for 2 h. p53-FKBP12F36 V-HA was immunoprecipitated and acetylation monitored via immunoblotting. Results are representative of two independent biological replicates. Statistical significance was calculated with unpaired two-tailed Student’s t tests comparing DMSO- to AceTAGp300/CBP-1-treated samples.*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Data are plotted as mean ± s.d. of n = 2 independent biological replicates. Full image of immunoblots are shown in Figure S6.CC BY-NC-ND · PubMed Central
Figure 2 AceTAG mediated p300/CBP and PCAF/GCN5 recruitment mediates p53 stability and transcriptional activation. (a, b) AceTAG-mediated acetylation enhances p53 stability. Doxycycline-inducible p53-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h followed by DMSO, 3 μM AceTAGp300/CBP-1 or 3 μM AceTAGPCAF/GCN5-4 for 24 h. AceTAG was maintained or washed out from the cells and incubated for additional 1 h, followed by 50 μg/mL cycloheximide (CHX) treatment for indicated time to block protein synthesis. p53-FKBP12F36 V and acetylation of p53-FKBP12F36 V were monitored by immunoblots and quantified. Data are plotted as mean ± s.d. of n = 3 (a) or n = 2 (b) independent biological replicates. Statistical significance was calculated with unpaired two-tailed Student’s t tests comparing DMSO- to AceTAG-treated samples (black) or AceTAG-treated samples with or without washout (red) at each time points. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Full image of immunoblots are provided in Figure S7. Volcano plot of differential gene expression mediated by (d) AceTAGp300/CBP-1 and (e) AceTAGPCAF/GCN5-4 (24 h) in p53-FKBP12F36 V-HA H1299 cells. Vertical dashed lines correspond to 2-fold threshold relative to DMSO and horizontal lines corresponds to a p-value of 0.05 across biological triplicates. (e) AceTAG-mediated p53 acetylation induces transcriptional activation. p53-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle (noninduced) for 4 h and treated with DMSO, 3 μM AceTAGp300/CBP-1 or 3 μM AceTAGPCAF/GCN5-4 for 24 h. Heatmap depicting transcriptome changes in p53-FKBP12F36 V-HA H1299 cells mediated by AceTAGp300/CBP-1 and AceTAGPCAF/GCN5-4 treatment (24 h) using DESeq2 normalized count. Results representative of three independent biological replicates. Group definitions: Group 1: AceTAGp300/CBP/DMSO and AceTAGPCAF/GCN5/DMSO > 2, adjusted p < 0.05; no significant changes for AceTAGp300/CBP/AceTAGPCAF/GCN5 (0.5 < fold change <2, and/or p > 0.05). Group 2: AceTAGp300/CBP/DMSO and AceTAGPCAF/GCN5/DMSO > 2, adjusted p < 0.05; AceTAGp300/CBP/AceTAGPCAF/GCN5 > 2, adjusted p < 0.05. Group 3: AceTAGp300/CBP/DMSO > 2, adjusted p < 0.05; no significant changes for AceTAGPCAF/GCN5/DMSO (0.5 < fold change <2, and/or p > 0.05) ; AceTAGp300/CBP/AceTAGPCAF/GCN5 > 2, adjusted p < 0.05. Group 4: AceTAGp300/CBP/DMSO > 2, p < 0.05; no significant changes for AceTAGPCAF/GCN5/DMSO and AceTAGp300/CBP/ AceTAGPCAF/GCN5 (0.5 < fold change <2, and/or p > 0.05). Group 5: AceTAGp300/CBP/DMSO < 2 and AceTAGPCAF/GCN5/DMSO > 2, p < 0.05; no significant changes for AceTAGp300/CBP/AceTAGPCAF/GCN5 (0.5 < fold change <2, and/or p > 0.05). Group 6: AceTAGp300/CBP/DMSO < 0.5, adjusted p < 0.05 and/or AceTAGPCAF/GCN5 < 0.5 adjusted p < 0.05.
Figure 2 AceTAG mediated p300/CBP and PCAF/GCN5 recruitment mediates p53 stability and transcriptional activation. (a, b) AceTAG-mediated acetylation enhances p53 stability. Doxycycline-inducible p53-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h followed by DMSO, 3 μM AceTAGp300/CBP-1 or 3 μM AceTAGPCAF/GCN5-4 for 24 h. AceTAG was maintained or washed out from the cells and incubated for additional 1 h, followed by 50 μg/mL cycloheximide (CHX) treatment for indicated time to block protein synthesis. p53-FKBP12F36 V and acetylation of p53-FKBP12F36 V were monitored by immunoblots and quantified. Data are plotted as mean ± s.d. of n = 3 (a) or n = 2 (b) independent biological replicates. Statistical significance was calculated with unpaired two-tailed Student’s t tests comparing DMSO- to AceTAG-treated samples (black) or AceTAG-treated samples with or without washout (red) at each time points. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Full image of immunoblots are provided in Figure S7. Volcano plot of differential gene expression mediated by (d) AceTAGp300/CBP-1 and (e) AceTAGPCAF/GCN5-4 (24 h) in p53-FKBP12F36 V-HA H1299 cells. Vertical dashed lines correspond to 2-fold threshold relative to DMSO and horizontal lines corresponds to a p-value of 0.05 across biological triplicates. (e) AceTAG-mediated p53 acetylation induces transcriptional activation. p53-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle (noninduced) for 4 h and treated with DMSO, 3 μM AceTAGp300/CBP-1 or 3 μM AceTAGPCAF/GCN5-4 for 24 h. Heatmap depicting transcriptome changes in p53-FKBP12F36 V-HA H1299 cells mediated by AceTAGp300/CBP-1 and AceTAGPCAF/GCN5-4 treatment (24 h) using DESeq2 normalized count. Results representative of three independent biological replicates. Group definitions: Group 1: AceTAGp300/CBP/DMSO and AceTAGPCAF/GCN5/DMSO > 2, adjusted p < 0.05; no significant changes for AceTAGp300/CBP/AceTAGPCAF/GCN5 (0.5 < fold change <2, and/or p > 0.05). Group 2: AceTAGp300/CBP/DMSO and AceTAGPCAF/GCN5/DMSO > 2, adjusted p < 0.05; AceTAGp300/CBP/AceTAGPCAF/GCN5 > 2, adjusted p < 0.05. Group 3: AceTAGp300/CBP/DMSO > 2, adjusted p < 0.05; no significant changes for AceTAGPCAF/GCN5/DMSO (0.5 < fold change <2, and/or p > 0.05) ; AceTAGp300/CBP/AceTAGPCAF/GCN5 > 2, adjusted p < 0.05. Group 4: AceTAGp300/CBP/DMSO > 2, p < 0.05; no significant changes for AceTAGPCAF/GCN5/DMSO and AceTAGp300/CBP/ AceTAGPCAF/GCN5 (0.5 < fold change <2, and/or p > 0.05). Group 5: AceTAGp300/CBP/DMSO < 2 and AceTAGPCAF/GCN5/DMSO > 2, p < 0.05; no significant changes for AceTAGp300/CBP/AceTAGPCAF/GCN5 (0.5 < fold change <2, and/or p > 0.05). Group 6: AceTAGp300/CBP/DMSO < 0.5, adjusted p < 0.05 and/or AceTAGPCAF/GCN5 < 0.5 adjusted p < 0.05.CC BY-NC-ND · PubMed Central
Figure 3 Mechanistic investigations of AceTAG-induced p53 transcriptional activity. (a) Increased p53 localization to CDKN1A promoter by AceTAG-mediated p53 acetylation as determined by ChIP-qPCR. p53-FKBP12F36 V-HA H1299 cells pretreated with 1 μg/mL doxycycline or vehicle for 4 h followed by DMSO or 3 μM AceTAGp300/CBP-1 for 4 h. AceTAGp300/CBP-1 was maintained or washed out from cells and incubated for additional 4 h. p53-FKBP12F36 V-HA-DNA cross-linked complex was enriched, extracted and subjected to qPCR analysis. Statistical significance was calculated with unpaired two-tailed Student’s t tests comparing DMSO- to AceTAGp300/CBP-1-treated samples.*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Data are plotted as mean ± s.d. of n = 2 independent biological replicates. (b) ChIP-qPCR of H3Ac localization at CDKN1A promoter. p53-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h followed by DMSO or 3 μM AceTAGp300/CBP-1 for 4 h. For benchmark experiments of H3Ac, p53-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h followed by DMSO or 5 μM SAHA for 2 h. Statistical significance was calculated with unpaired two-tailed Student’s t tests comparing DMSO- to AceTAGp300/CBP-1-treated samples. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Data are plotted as mean ± s.d. of n = 2 independent biological replicates. (c) p53-FKBP12F36 V acetylation and p21 expression after washout. p53-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h and treated with DMSO or 3 μM AceTAGp300/CBP-1 for 4 h. AceTAGp300/CBP-1 was maintained or washed out of cells and incubated for indicated time. The results are representative of two independent biological replicates. Full image of immunoblots are provided in Figure S8. (d) Schematic hypothesis of AceTAG-induced p53 localization to its target gene promoter.
Figure 3 Mechanistic investigations of AceTAG-induced p53 transcriptional activity. (a) Increased p53 localization to CDKN1A promoter by AceTAG-mediated p53 acetylation as determined by ChIP-qPCR. p53-FKBP12F36 V-HA H1299 cells pretreated with 1 μg/mL doxycycline or vehicle for 4 h followed by DMSO or 3 μM AceTAGp300/CBP-1 for 4 h. AceTAGp300/CBP-1 was maintained or washed out from cells and incubated for additional 4 h. p53-FKBP12F36 V-HA-DNA cross-linked complex was enriched, extracted and subjected to qPCR analysis. Statistical significance was calculated with unpaired two-tailed Student’s t tests comparing DMSO- to AceTAGp300/CBP-1-treated samples.*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Data are plotted as mean ± s.d. of n = 2 independent biological replicates. (b) ChIP-qPCR of H3Ac localization at CDKN1A promoter. p53-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h followed by DMSO or 3 μM AceTAGp300/CBP-1 for 4 h. For benchmark experiments of H3Ac, p53-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h followed by DMSO or 5 μM SAHA for 2 h. Statistical significance was calculated with unpaired two-tailed Student’s t tests comparing DMSO- to AceTAGp300/CBP-1-treated samples. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Data are plotted as mean ± s.d. of n = 2 independent biological replicates. (c) p53-FKBP12F36 V acetylation and p21 expression after washout. p53-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h and treated with DMSO or 3 μM AceTAGp300/CBP-1 for 4 h. AceTAGp300/CBP-1 was maintained or washed out of cells and incubated for indicated time. The results are representative of two independent biological replicates. Full image of immunoblots are provided in Figure S8. (d) Schematic hypothesis of AceTAG-induced p53 localization to its target gene promoter.CC BY-NC-ND · PubMed Central
Figure 4 AceTAG induces mutant p53 acetylation, target gene activation, and stability in cells. (a–c) Immunoblot analysis of AceTAG-induced p53V157F, p53Y220C, and p53R248W acetylation. (a) p53 V157F-FKBP12F36 V-HA, (b) p53Y220C-FKBP12F36 V-HA, or (f) p53R248W-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 16 h followed by DMSO or increasing concentration of AceTAGp300/CBP-1 for 2 h. The results are representative of two independent biological replicates. (d–f) Immunoblot analysis of AceTAG-induced p53 V157F, p53Y220C, and p53R248W stability. (d) p53 V157F-FKBP12F36 V-HA, (e) p53Y220C-FKBP12F36 V-HA, or (f) p53R248W-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h followed by DMSO or 3 μM AceTAGp300/CBP-1 for 24 h, and then 50 μg/mL cycloheximide (CHX) treatment for indicated time to block protein synthesis. Quantitation shown to the right of each immunoblot plotted as mean ± s.d. of n = 2 independent biological replicates. (g–i) Immunoblot analysis of AceTAG-induced p21 activation in mutant cell lines. (g) p53 V157F-FKBP12F36 V-HA, (h) p53Y220C-FKBP12F36 V-HA, or (i) p53R248W-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h and treated with DMSO or increasing concentration of AceTAGp300/CBP-1 for 24 h. Results representative of three independent biological replicates. Full image of immunoblots are provided in Figure S9.
Figure 4 AceTAG induces mutant p53 acetylation, target gene activation, and stability in cells. (a–c) Immunoblot analysis of AceTAG-induced p53V157F, p53Y220C, and p53R248W acetylation. (a) p53 V157F-FKBP12F36 V-HA, (b) p53Y220C-FKBP12F36 V-HA, or (f) p53R248W-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 16 h followed by DMSO or increasing concentration of AceTAGp300/CBP-1 for 2 h. The results are representative of two independent biological replicates. (d–f) Immunoblot analysis of AceTAG-induced p53 V157F, p53Y220C, and p53R248W stability. (d) p53 V157F-FKBP12F36 V-HA, (e) p53Y220C-FKBP12F36 V-HA, or (f) p53R248W-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h followed by DMSO or 3 μM AceTAGp300/CBP-1 for 24 h, and then 50 μg/mL cycloheximide (CHX) treatment for indicated time to block protein synthesis. Quantitation shown to the right of each immunoblot plotted as mean ± s.d. of n = 2 independent biological replicates. (g–i) Immunoblot analysis of AceTAG-induced p21 activation in mutant cell lines. (g) p53 V157F-FKBP12F36 V-HA, (h) p53Y220C-FKBP12F36 V-HA, or (i) p53R248W-FKBP12F36 V-HA H1299 cells were pretreated with 1 μg/mL doxycycline or vehicle for 4 h and treated with DMSO or increasing concentration of AceTAGp300/CBP-1 for 24 h. Results representative of three independent biological replicates. Full image of immunoblots are provided in Figure S9.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. Waldman T., 1995, Cancer Res., 55, 5187
  2. Scolnick D. M., 1997, Cancer Res., 57, 3693
  3. Mehta S., 2023, Methods in Enzymology, 1

Cited by

See all 19

Metadata

Authors
Chen, L.-Y., Singha Roy, S. J., Jadhav, A. M., Wang, W. W., Chen, P.-H., Bishop, T., Erb, M. A., & Parker, C. G.
Affiliations
  • Department of Chemistry
  • Scripps Research Institute (US)
Corresponding author
Parker, Christopher G.
Venue
ACS Chemical Biology
Published
2024-09-09
Volume
19
Issue
9
Pages
1918-1929
ISSN
  • 1554-8929 (ISSN-L)
  • 1554-8937
OpenAlex
W4402349055
Cited by
18
References
117
Citations by year
2026: 11 · 2025: 6 · 2024: 1
FWCI
3.07
Type
journal article
Language
en
Open access
Locations
  • ACS Chemical Biology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (R01CA280720)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Keywords
p53 acetylation, CBP/p300, post-translational modification, p53 stabilization, transcriptional activity, cancer cells, acetyltransferase
MeSH terms
p300-CBP-Associated Factor, Acetylation, Humans, Protein Processing, Post-Translational, Tumor Suppressor Protein p53, Cell Line, Tumor, p300-CBP Transcription Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.